Iron Supplementation in CML with Low Hemoglobin
Do not give iron supplementation to patients with chronic myeloid leukemia (CML) who have low hemoglobin unless you have documented true iron deficiency (ferritin <30 ng/mL and transferrin saturation <15%). The primary concern in CML is avoiding iron overload, which worsens survival and increases treatment-related mortality, not treating presumed iron deficiency 1.
Critical Distinction: CML is NOT an Iron Deficiency State
CML patients with anemia typically have anemia of chronic disease (functional iron deficiency) rather than true iron deficiency. The evidence provided focuses heavily on myelodysplastic syndromes (MDS) and other malignancies, but the principles regarding iron overload apply directly to CML:
- Iron overload significantly worsens survival in hematologic malignancies requiring transfusions 1
- Elevated ferritin (>1,000 ng/mL) increases mortality risk by 30% for every 500 ng/mL increase 1
- Pre-transplant iron overload increases treatment-related mortality in patients undergoing allogeneic stem cell transplantation 1—a critical consideration since transplant remains an important option for CML patients who fail TKI therapy 2, 3
When to Consider Iron Supplementation
Only supplement iron if you document absolute iron deficiency:
- Ferritin <30 ng/mL AND
- Transferrin saturation <15% 4
Check iron studies before any supplementation:
- Serum ferritin
- Transferrin saturation (TSAT)
- Consider trending ferritin over time to account for inflammation 1
Management Algorithm for Low Hemoglobin in CML
Step 1: Identify the Cause
- TKI-related myelosuppression is the most common cause 3, 5
- Check iron studies (ferritin, TSAT)
- Rule out bleeding, hemolysis, nutritional deficiencies (B12, folate)
Step 2: Address Based on Iron Status
If absolute iron deficiency (ferritin <30, TSAT <15%):
- Intravenous iron is preferred over oral 4
- Use low-molecular-weight iron dextran, ferric gluconate, or iron sucrose 4
- Monitor ferritin—do NOT exceed 500 ng/mL to avoid toxicity 6
If functional iron deficiency or normal iron stores:
- Do NOT give iron supplementation
- Consider supportive measures:
Step 3: Optimize TKI Management
- Ensure medication adherence 3
- Consider dose adjustments if myelosuppression is severe
- Provide appropriate supportive care rather than reflexively adding iron 2
Critical Pitfalls to Avoid
Do not assume low hemoglobin = iron deficiency in CML patients. This is the most common error. The anemia in CML is typically:
- Related to TKI therapy (myelosuppression) 3, 5
- Anemia of chronic disease (functional iron deficiency)
- Disease-related bone marrow dysfunction
Do not give empiric iron without checking iron studies. Iron overload causes:
- Cardiac disease (leading cause of death in transfusion-dependent patients) 1
- Liver disease and endocrine dysfunction 1
- Increased leukemic transformation risk 1
- Worse transplant outcomes 1
Monitor ferritin levels if iron is given. Keep ferritin <500 ng/mL, especially in younger patients 6. Iron overload defined as ferritin >1,000 ng/mL significantly worsens survival 1.
Special Consideration: Transfusion-Dependent CML
If your CML patient becomes transfusion-dependent:
- Consider iron chelation therapy rather than iron supplementation 1
- Monitor ferritin and TSAT regularly 1
- Evaluate for disease progression or TKI resistance 2, 3
Evidence Quality Note
The provided guidelines focus on MDS [1-1] and cancer-related anemia 4, not specifically CML. However, the principles of iron metabolism in hematologic malignancies are directly applicable. The key message is consistent across all evidence: iron overload is harmful in hematologic malignancies, and iron supplementation should only be given for documented absolute iron deficiency 1, 4, 6.